Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Decoy Therapeutics will use the platform, with funding support from the Gates Foundation, to provide widespread access to peptide-conjugate antivirals from Decoy's IMP3ACT™   platform for low- and middle-income countries. CAMBRIDGE, Mass. and HOUSTON, Jan.